16 Sep 2021 17:00
REACH
16 September 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Official Opening of New Cardiff Headquarters
Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at 1 Caspian Point in Cardiff, UK.
The Company has moved to the 1 Caspian Point building, part of the Parmer Cardiff campus on the city's waterfront, where it has created 8,050 sq ft of offices and laboratories on the ground and first floors. This new headquarters provides bespoke accommodation to facilitate the Company's future plans, particularly with its programmes ustilising its Q-Sphera 3D printing technology to encapsulate medicines in bio-degradable polymers for improved delivery and targeting.
Stephen Stamp, Chief Executive Officer of Midatech, said: "Our technology is unique and patented and we have identified a strategy to work on multiple Q-Sphera programmes simultaneously and partner them at an early stage.
"To execute on that plan Midatech needed expanded, purpose-designed labs, as our previous facilities were far from ideal with labs split over two floors and difficulties moving materials and equipment in and out. The new premises at Caspian Point have achieved this without a material increase in our costs and are modern, 50 per cent larger, and much more usable, with a layout tailored to suit our needs exactly, with capacity for further expansion."
Vaughan Gething MS, Welsh Government Minister for the Economy, when officially opening the new Midatech headquarters said: "Our ambition is for Wales to be a global leader in Life Sciences, whilst stimulating economic growth and creating new high-skilled jobs. We are already able to provide the right environment for companies to innovate and grow and, working alongside the NHS, together we can tackle the greatest healthcare challenges of our generation and address health inequalities. I'm very pleased to see how this business has grown and will play an important part in Wales' expanding Life Sciences sector."
For more information, please contact:
Midatech Pharma PLC |
Stephen Stamp, CEO, CFO |
Tel: +44 (0)29 2048 0180 |
www.midatechpharma.com |
|
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) |
Freddy Crossley, Emma Earl (Corporate Finance) |
Rupert Dearden (Corporate Broking) |
Tel: +44 (0)20 7886 2500 |
|
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050
|
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Email: midatech@investor-focus.co.uk |
|
Edison Group (US Investor Relations) Maxwell Colbert Tel: +1 (646) 653 7028 Email: mcolbert@edisongroup.com
|
About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com |